IC
ACHL

Ikarian Capital’s Achilles Therapeutics ACHL Stock Holding History

Ikarian Capital’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,441,141
Closed -$1.64M – 228
2024
Q4 		$1.64M Sell
1,441,141
-2,040
-0.1% -$2.1K 0.22% 88
2024
Q3 		$1.47M Hold
1,443,181
– – 0.21% 82
2024
Q2 		$1.18M Hold
1,443,181
– – 0.2% 68
2024
Q1 		$1.8M Buy
+1,443,181
New +$1.56M 0.2% 92

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Ikarian Capital's ACHL Position: Q1 2025 in Review

Ikarian Capital sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 1,441,141 shares — an estimated $1.64M sold.

Ikarian Capital first reported a position in ACHL in Q1 2024 and held it in 4 quarters. The position peaked at $1.8M in Q1 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Ikarian Capital reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 1,441,141 Achilles Therapeutics shares in Q1 2025, an estimated $1.64M.
  • Ikarian Capital first reported a position in Achilles Therapeutics in Q1 2024 and held it in 4 quarters.
  • Ikarian Capital's Achilles Therapeutics position peaked at $1.8M in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.